相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial
Masakazu Abe et al.
SUPPORTIVE CARE IN CANCER (2016)
Drug-drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical data
James J. Natale et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2016)
Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study
F. Roila et al.
ANNALS OF ONCOLOGY (2015)
Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron)
Camilo Rojas et al.
CANCER TREATMENT REVIEWS (2015)
Olanzapine for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): Alliance A221301, a randomized, double-blind, placebo-controlled trial
Rudolph M. Navari et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial
Lee S. Schwartzberg et al.
LANCET ONCOLOGY (2015)
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials
Bernardo L. Rapoport et al.
LANCET ONCOLOGY (2015)
Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemotherapy (HEC)
Meinolf Karthaus et al.
SUPPORTIVE CARE IN CANCER (2015)
Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC)
Bernardo Rapoport et al.
SUPPORTIVE CARE IN CANCER (2015)
Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial
Harry Raftopoulos et al.
SUPPORTIVE CARE IN CANCER (2015)
Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study
P. J. Hesketh et al.
ANNALS OF ONCOLOGY (2014)
A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy
R. J. Gralla et al.
ANNALS OF ONCOLOGY (2014)
A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy
M. Aapro et al.
ANNALS OF ONCOLOGY (2014)
5-Hydroxytryptamine3 receptor antagonists and cardiac side effects
Louise Brygger et al.
EXPERT OPINION ON DRUG SAFETY (2014)
Aprepitant Versus Dexamethasone for Preventing Chemotherapy-Induced Delayed Emesis in Patients With Breast Cancer: A Randomized Double-Blind Study
Fausto Roila et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly or Moderately Emetogenic Chemotherapy: A Randomized, Double-Blind, Placebo-Controlled Study
Naomi Mizukami et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2014)
Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial
Zhihuang Hu et al.
SUPPORTIVE CARE IN CANCER (2014)
Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial
H. Saito et al.
ANNALS OF ONCOLOGY (2013)
Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials
Luigi Celio et al.
SUPPORTIVE CARE IN CANCER (2013)
Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial
Ralph Boccia et al.
SUPPORTIVE CARE IN CANCER (2013)
Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives
Selma Calcagnile et al.
SUPPORTIVE CARE IN CANCER (2013)
Equivalent Dynamic Human Brain NK1-Receptor Occupancy Following Single-Dose i.v. Fosaprepitant vs. Oral Aprepitant as Assessed by PET Imaging
K. Van Laere et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Prevention of Delayed Nausea: A University of Rochester Cancer Center Community Clinical Oncology Program Study of Patients Receiving Chemotherapy
Joseph A. Roscoe et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol-EASE
Steven Grunberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial
Luigi Celio et al.
SUPPORTIVE CARE IN CANCER (2011)
Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy
Mark G. Kris et al.
SUPPORTIVE CARE IN CANCER (2011)
Acute emesis: moderately emetogenic chemotherapy
Jorn Herrstedt et al.
SUPPORTIVE CARE IN CANCER (2011)
Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study
Ralph V. Boccia et al.
SUPPORTIVE CARE IN CANCER (2011)
Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy
M. Aapro et al.
ANNALS OF ONCOLOGY (2010)
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference
F. Roila et al.
ANNALS OF ONCOLOGY (2010)
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study
Bernardo L. Rapoport et al.
SUPPORTIVE CARE IN CANCER (2010)
Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
Jorn Herrstedt et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting
Lijun Tan et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2009)
Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial
Steven M. Grunberg et al.
LANCET ONCOLOGY (2009)
Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment
H. J. Schmoll et al.
ANNALS OF ONCOLOGY (2006)
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy
DG Warr et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide
F Roila
JOURNAL OF CLINICAL ONCOLOGY (2004)
Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant
RI Sanchez et al.
DRUG METABOLISM AND DISPOSITION (2004)
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - The Aprepitant Protocol 052 Study Group
PJ Hesketh et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe
AK Majumdar et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
分享论文
